変形性関節症治療薬の世界市場:部位別、薬剤タイプ別2024年予測
Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024
- 出版元:MarketsandMarkets
出版元について
- 発行年:2019年10月
- 定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算(お見積り日TTSレート)となります。
- 納品形態:PDF by Email
- 当調査レポートは英文148ページになります。
- 商品コード:MAM1722
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
変形性関節症治療薬の世界市場規模は2019年の推計68億ドルから、今後2024年には101億ドルにまで増加すると予測されます。当レポートでは、2024年に至る変形性関節症治療薬の世界市場予測(市場規模US$)、部位別市場(変形性膝関節症、変形性股関節症、変形性手関節症、変形性小関節症)、薬剤タイプ別市場(関節内補充薬、非ステロイド性抗炎症薬各種、鎮痛薬各種、コルチコステロイド)、投薬経路別市場(経口、非経口、局所)、流通経路別市場(病院薬局、オンライン薬局、小売薬局)、購買パターン別市場(処方薬、市販薬)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業15社プロフィール動向などの情報も交えて、変形性関節症治療薬市場の現在と今後展開を予測分析していきます。
【レポート構成概要】
◆変形性関節症治療薬の世界市場予測2017-2024年
・市場規模(US$)
◆部位別、市場-2024年
・変形性膝関節症
・変形性股関節症
・変形性手関節症
・変形性小関節症
※(市場規模US$)
◆薬剤タイプ別、市場-2024年
関節内補充薬
非ステロイド性抗炎症薬
・イブプロフェン
・ジクロフェナク
・アスピリン
・ナプロキセン
・その他
鎮痛薬
・アセトアミノフェン
・デュロキセチン
コルチコステロイド
※(市場規模US$)
◆投薬経路別、市場-2024年
・経口
・非経口
・局所
※(市場規模US$)
◆流通経路別、市場-2024年
・病院薬局
・オンライン薬局
・小売薬局
※(市場規模US$)
◆購買パターン別、市場-2024年
・処方薬
・市販薬
※(市場規模US$)
◆主要国地域別市場-2024年
欧州
・イタリア、ドイツ、スペイン
・フランス、英国
・その他欧州
北米
・米国、カナダ
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※国地域別に全てのセグメントの細分化データ掲載、詳細は目次参照
※(市場規模US$)
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・競合状況
◆変形性関節症治療薬の主要企業プロフィール動向
・SANOFI
・HORIZON THERAPEUTICS PLC
・JOHNSON & JOHNSON
・GLAXOSMITHKLINE PLC
・BAYER AG
・ABBOTT
・PFIZER, INC.
・ELI LILLY
・ANIKA THERAPEUTICS, INC.
・NOVARTIS
・FERRING PHARMACEUTICALS
・BIOVENTUS
・ZIMMER BIOMET HOLDINGS, INC.
・FIDIA FARMACEUTICI S.P.A.
・FLEXION THERAPEUTICS, INC.
(全148頁)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
英文詳細目次(table of contents)
【原文詳細目次】
Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024
Table of Contents
1.... INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED.. 18
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2.... RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY DATA
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH.. 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3.... EXECUTIVE SUMMARY
4.... PREMIUM INSIGHTS
4.1 OSTEOARTHRITIS THERAPEUTICS MARKET OVERVIEW
4.2 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY ANATOMY (2018)
4.3 GEOGRAPHICAL SNAPSHOT OF THE OSTEOARTHRITIS THERAPEUTICS MARKET
5.... MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 RAPID GROWTH IN THE GERIATRIC AND OBESE POPULATIONS AND
THE ASSOCIATED INCREASE IN THE PREVALENCE OF OSTEOARTHRITIS
5.2.1.2 INCREASING INCIDENCE OF SPORTS INJURIES
5.2.2 RESTRAINTS
5.2.2.1 RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN OSTEOARTHRITIS TREATMENT
5.2.3 OPPORTUNITIES
5.2.3.1 EMERGING MARKETS
5.2.3.2 STRATEGIC COLLABORATIONS FOCUSED ON NEW PRODUCT DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 AVAILABILITY OF ALTERNATIVE NON-DRUG PAIN MANAGEMENT THERAPIES
6.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY
6.1 INTRODUCTION
6.2 KNEE OSTEOARTHRITIS
6.2.1 RISING OBESE AND GERIATRIC POPULATIONS TO INCREASE THE PREVALENCE OF KNEE OSTEOARTHRITIS
6.3 HIP OSTEOARTHRITIS
6.3.1 SIMILAR TO KNEE OSTEOARTHRITIS, HIP OSTEOARTHRITIS IS MORE COMMON IN THE GERIATRIC AND OBESE POPULATIONS
6.4 HAND OSTEOARTHRITIS
6.4.1 RISING PREVALENCE OF SHOULDER OSTEOARTHRITIS TO DRIVE MARKET GROWTH
6.5 SMALL-JOINT OSTEOARTHRITIS
6.5.1 RISING NUMBER OF ANKLE-RELATED SPORTS INJURIES TO INCREASE
THE PREVALENCE OF ANKLE OSTEOARTHRITIS
7.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE
7.1 INTRODUCTION
7.2 VISCOSUPPLEMENTATION AGENTS
7.2.1 VISCOSUPPLEMENTATION AGENTS DOMINATED THE MARKET IN 2018
7.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. 47
7.3.1 NSAIDS CAN RELIEVE PAIN AND INFLAMMATION WITHOUT THE VARIOUS POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH CORTICOSTEROIDS
7.3.1.1 IBUPROFEN
7.3.1.2 DICLOFENAC
7.3.1.3 ASPIRIN
7.3.1.4 NAPROXEN
7.3.1.5 OTHER MOLECULES
7.4 ANALGESICS
7.4.1 ACETAMINOPHEN
7.4.2 DULOXETINE
7.5 CORTICOSTEROIDS
8.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 ORAL ROUTE
8.3 PARENTERAL ROUTE
8.4 TOPICAL ROUTE
9.... OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
9.1 INTRODUCTION
9.2 HOSPITAL PHARMACIES
9.3 ONLINE PHARMACIES
9.4 RETAIL PHARMACIES
10.. OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN
10.1 INTRODUCTION
10.2 PRESCRIPTION DRUGS
10.2.1 PRESCRIPTION DRUGS TO ACCOUNT FOR A LARGER SHARE OF THE MARKET
10.3 OVER-THE-COUNTER DRUGS
10.3.1 EASE OF PURCHASE AND ADMINISTRATION RESULTING IN A RISING DEMAND FOR OTC DRUGS
11.. OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION
11.1 INTRODUCTION
11.2 EUROPE
11.2.1 ITALY
11.2.2 GERMANY
11.2.3 SPAIN
11.2.4 FRANCE
11.2.5 UK
11.2.6 REST OF EUROPE
11.3 NORTH AMERICA
11.3.1 US
11.3.2 CANADA
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF ASIA PACIFIC
11.5 REST OF THE WORLD
12.. COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET RANKING ANALYSIS, 2018
12.3 COMPETITIVE SCENARIO
12.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016–2019
12.3.2 COLLABORATIONS, 2016–2019
12.3.3 EXPANSIONS, 2016–2019
12.3.4 ACQUISITIONS, 2016–2019
12.3.5 OTHER DEVELOPMENTS
12.4 COMPETITIVE LEADERSHIP MAPPING
12.4.1 VENDOR INCLUSION CRITERIA
12.4.2 VISIONARY LEADERS. 118
12.4.3 INNOVATORS
12.4.4 DYNAMIC DIFFERENTIATORS
12.4.5 EMERGING COMPANIES
13.. COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1 SANOFI
13.2 HORIZON THERAPEUTICS PLC
13.3 JOHNSON & JOHNSON
13.4 GLAXOSMITHKLINE PLC
13.5 BAYER AG
13.6 ABBOTT
13.7 PFIZER, INC.
13.8 ELI LILLY
13.9 ANIKA THERAPEUTICS, INC.
13.10 NOVARTIS
13.11 FERRING PHARMACEUTICALS
13.12 BIOVENTUS
13.13 ZIMMER BIOMET HOLDINGS, INC.
13.14 FIDIA FARMACEUTICI S.P.A.
13.15 FLEXION THERAPEUTICS, INC.
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14.. APPENDIX
LIST OF TABLES
TABLE 1 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 2 KNEE OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 3 HIP OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 4 HAND OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 5 SMALL-JOINT OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 6 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 7 OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 8 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 9 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 OSTEOARTHRITIS THERAPEUTICS MARKET FOR IBUPROFEN, BY REGION,
2017–2024 (USD MILLION)
TABLE 11 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DICLOFENAC, BY REGION,
2017–2024 (USD MILLION)
TABLE 12 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ASPIRIN, BY REGION,
2017–2024 (USD MILLION)
TABLE 13 OSTEOARTHRITIS THERAPEUTICS MARKET FOR NAPROXEN, BY REGION,
2017–2024 (USD MILLION)
TABLE 14 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OTHER MOLECULES, BY REGION, 2017–2024 (USD MILLION)
TABLE 15 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 16 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION,
2017–2024 (USD MILLION)
TABLE 17 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ACETAMINOPHEN, BY REGION, 2017–2024 (USD MILLION)
TABLE 18 OSTEOARTHRITIS THERAPEUTICS MARKET FOR DULOXETINE, BY REGION,
2017–2024 (USD MILLION)
TABLE 19 OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION)
TABLE 21 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PARENTERAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 OSTEOARTHRITIS THERAPEUTICS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL,
2017–2024 (USD MILLION)
TABLE 25 OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES,
BY REGION, 2017–2024 (USD MILLION)
TABLE 26 OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 29 OSTEOARTHRITIS THERAPEUTICS MARKET FOR PRESCRIPTION DRUGS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 30 OSTEOARTHRITIS THERAPEUTICS MARKET FOR OVER-THE-COUNTER DRUGS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 31 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 32 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 34 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 35 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 36 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 37 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 38 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 39 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 40 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 41 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 42 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 43 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 44 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 45 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 46 ITALY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 47 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 48 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 49 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 50 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 51 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 52 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 53 GERMANY: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 54 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 55 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 56 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 57 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 58 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 59 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 60 SPAIN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 61 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 62 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 63 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 65 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 66 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 67 FRANCE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 68 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 69 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 70 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 71 UK: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 72 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 73 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 74 UK: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 75 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 76 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 77 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 78 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 79 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 80 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 81 ROE: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 82 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 83 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 84 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2017–2024 (USD MILLION)
TABLE 85 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 87 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 88 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 89 NORTH AMERICA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 90 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 91 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 92 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 93 US: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 94 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 95 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 96 US: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2017–2024 (USD MILLION)
TABLE 97 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 98 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 99 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 101 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 102 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 103 CANADA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 104 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 105 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 106 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 107 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 108 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 109 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 110 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 111 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET,
BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 112 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 113 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 114 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 115 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 116 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 117 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 118 JAPAN: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 119 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 120 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 121 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 122 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 123 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 124 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 125 CHINA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 126 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 127 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 128 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 129 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 130 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 131 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 132 INDIA: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 133 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 134 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 135 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 136 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 137 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 138 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 139 ROAPAC: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
TABLE 140 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2017–2024 (USD MILLION)
TABLE 141 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2017–2024 (USD MILLION)
TABLE 142 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 143 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET FOR NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS, BY MOLECULE, 2017–2024 (USD MILLION)
TABLE 144 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION)
TABLE 145 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017–2024 (USD MILLION)
TABLE 146 ROW: OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN, 2017–2024 (USD MILLION)
LIST OF FIGURES
FIGURE 1 OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4 OSTEOARTHRITIS THERAPEUTICS MARKET: BOTTOM-UP APPROACH
FIGURE 5 OSTEOARTHRITIS THERAPEUTICS MARKET: TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY,
2019 VS. 2024 (USD BILLION)
FIGURE 8 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE,
2019 VS. 2024 (USD BILLION)
FIGURE 9 OSTEOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION,
2019 VS. 2024 (USD BILLION)
FIGURE 10 OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL,
2019 VS. 2024 (USD BILLION)
FIGURE 11 OSTEOARTHRITIS THERAPEUTICS MARKET, BY PURCHASING PATTERN,
2019 VS. 2024 (USD BILLION)
FIGURE 12 OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION,
2019 VS. 2024 (USD BILLION)
FIGURE 13 HIGH AND GROWING PREVALENCE OF OSTEOARTHRITIS IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET
FIGURE 14 KNEE OSTEOARTHRITIS THERAPEUTICS SEGMENT TO DOMINATE
THE EUROPEAN MARKET IN 2019
FIGURE 15 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 16 OSTEOARTHRITIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17 GERIATRIC POPULATION, BY REGION, 2017 VS. 2050
FIGURE 18 EUROPE: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: OSTEOARTHRITIS THERAPEUTICS MARKET SNAPSHOT
FIGURE 20 KEY DEVELOPMENTS IN THE OSTEOARTHRITIS THERAPEUTICS MARKET FROM JANUARY 2016 TO AUGUST 2019
FIGURE 21 TOP 5 COMPANIES IN THE OSTEOARTHRITIS THERAPEUTICS MARKET
FIGURE 22 GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET: COMPETITIVE
LEADERSHIP MAPPING, 2019
FIGURE 23 SANOFI: COMPANY SNAPSHOT (2018)
FIGURE 24 HORIZON THERAPEUTICS PLC: COMPANY SNAPSHOT (2018)
FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018)
FIGURE 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
FIGURE 27 BAYER AG: COMPANY SNAPSHOT (2018)
FIGURE 28 ABBOTT: COMPANY SNAPSHOT (2018)
FIGURE 29 PFIZER, INC.: COMPANY SNAPSHOT (2018)
FIGURE 30 ELI LILLY: COMPANY SNAPSHOT (2018)
FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 32 NOVARTIS: COMPANY SNAPSHOT (2018)
FIGURE 33 ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 34 FLEXION THERAPEUTICS: COMPANY SNAPSHOT (2018)
掲載企業リスト
プレスリリース
プレスリリース
当レポートのプレスリリースは発行されておりません。